Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea

Published 17/07/2025, 15:38
© Reuters

Investing.com -- Morgan Stanley identified Bristol-Myers Squibb (NYSE:BMY) as a catalyst-driven idea ahead of a key data readout for Cobenfy in Alzheimer’s Disease Psychosis (ADP), expected in late third or early fourth quarter.

Cobenfy, approved by the U.S. Food and Drug Administration for schizophrenia in September 2024, is “one of the company’s key new product cycles,” according to Morgan Stanley (NYSE:MS). 

The drug was added to BMY’s pipeline through its acquisition of Karuna in December 2023 and is central to its strategy to offset upcoming losses of exclusivity.

The upcoming readout from the ADEPT-2 Phase 3 trial is the first of three studies evaluating Cobenfy in ADP. 

BMY has indicated that approval in this indication would require positive results from two Phase 3 trials. 

The analysts wrote, “In the event of positive ADEPT-2 data… we expect the magnitude of potential upside stock move in BMY shares to be somewhat driven by how Cobenfy ramps in schizophrenia in 2H25.”

Morgan Stanley outlined three scenarios for the stock: a low-single-digit percentage gain if script growth remains muted; a mid-single-digit gain if growth accelerates; or a decline of more than 5% in the event of a trial failure.

“Our base case expectation is Scenario 1 (40% probability),” Morgan Stanley said, adding that it models risk-adjusted 2033 Cobenfy sales of $5 billion, with $1.9 billion coming from ADP at a 60% probability of success.

The note also pointed to recent moderation in Cobenfy prescriptions for schizophrenia, which could influence market reaction depending on second-half trends.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.